Brigham and Women's Rheumatoid Arthritis Sequential Study
BRASS
1 other identifier
observational
1,598
1 country
1
Brief Summary
The goal of the present study is to establish a prospective observational cohort of Rheumatoid Arthritis patients in order to
- 1.Determine and validate biomarkers that predict drug response and toxicity in RA.
- 2.Determine and validate biomarkers that predict disease activity and prognosis in RA.
- 3.Evaluate the natural history of treated RA in terms of its clinical, functional and economic outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2003
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2003
CompletedFirst Submitted
Initial submission to the registry
February 14, 2013
CompletedFirst Posted
Study publicly available on registry
February 15, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2028
September 26, 2025
September 1, 2025
25 years
February 14, 2013
September 23, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Determine and validate biomarkers that predict drug response and toxicity in RA.
Determine and validate biomarkers that predict drug response and toxicity in RA.
15 years
Secondary Outcomes (2)
Determine and validate biomarkers that predict disease activity and prognosis in RA.
15 years
Evaluate the natural history of treated RA in terms of its clinical, functional and economic outcomes.
15 years
Eligibility Criteria
Adults 18 years or older with Rheumatoid Arthritis
You may qualify if:
- Are 18 years of age or older;
- Are a patient registered at the R.B.Brigham Arthritis Center.
- Have, at the time of enrollment a diagnosis of RA made by a board certified rheumatologist.
- Are able and willing to provide informed consent.
You may not qualify if:
- less than 18 years of age
- do not have a diagnosis of RA
- have a history of SLE or Psoriasis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Brigham and Women's Hospitallead
- Crescendo Biosciencecollaborator
- Bristol-Myers Squibbcollaborator
- UCB Pharmacollaborator
- Sanoficollaborator
- Janssen, LPcollaborator
- Aqtual, Inc.collaborator
Study Sites (1)
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Related Publications (7)
Shadick N, Hagino O, Praestgaard A, Fiore S, Weinblatt M, Burmester G. Association of hemoglobin levels with radiographic progression in patients with rheumatoid arthritis: an analysis from the BRASS registry. Arthritis Res Ther. 2023 May 27;25(1):88. doi: 10.1186/s13075-023-03068-w.
PMID: 37237405DERIVEDZhuo J, Xia Q, Sharma N, Gao S, Lama S, Cui J, Feathers V, Shadick N, Weinblatt ME. The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity. Rheumatol Ther. 2022 Apr;9(2):637-647. doi: 10.1007/s40744-022-00427-y. Epub 2022 Feb 16.
PMID: 35174462DERIVEDShadick NA, Gerlanc NM, Frits ML, Stolshek BS, Brady BL, Iannaccone C, Collier D, Cui J, Mutebi A, Weinblatt ME. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry. Clin Rheumatol. 2019 Nov;38(11):3081-3092. doi: 10.1007/s10067-019-04649-4. Epub 2019 Jul 29.
PMID: 31353421DERIVEDAlemao E, Iannaccone CK, Weinblatt ME, Shadick NA. Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients a US Observational Cohort. Clin Ther. 2019 Jun;41(6):1057-1065.e3. doi: 10.1016/j.clinthera.2019.04.029. Epub 2019 May 23.
PMID: 31130229DERIVEDAhmad HA, Alemao E, Guo Z, Iannaccone CK, Frits ML, Weinblatt M, Shadick NA. Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort. Adv Ther. 2018 Feb;35(2):232-242. doi: 10.1007/s12325-017-0657-x. Epub 2018 Jan 25.
PMID: 29368271DERIVEDAlemao E, Guo Z, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME. Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study. Semin Arthritis Rheum. 2018 Apr;47(5):630-638. doi: 10.1016/j.semarthrit.2017.10.009. Epub 2017 Oct 13.
PMID: 29241640DERIVEDAlemao E, Joo S, Kawabata H, Al MJ, Allison PD, Rutten-van Molken MP, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME. Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. Arthritis Care Res (Hoboken). 2016 Mar;68(3):308-17. doi: 10.1002/acr.22678.
PMID: 26238974DERIVED
Biospecimen
whole blood, serum, DNA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nancy A Shadick, MD, MPH
Brigham and Women's Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 20 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
February 14, 2013
First Posted
February 15, 2013
Study Start
March 1, 2003
Primary Completion (Estimated)
March 1, 2028
Study Completion (Estimated)
March 1, 2028
Last Updated
September 26, 2025
Record last verified: 2025-09